Chronic kidney disease at stage of 3, 4 and 5
Conditions
Interventions
Eligible patients with CKD stage 3, 4 and 5 were enrolled in a parallel, open-label, placebo controlled, randomized treatment protocol. During a run-in phase of about one month, all patients received
50 beats/min or arterial hypotension (BP <
90/60 mm Hg), it was temporarily halved, then again increased at same interval. The final dose of carvedilol was individually titrated. At the end of the up-titration phase, the therapy with carvedilo
Sponsors
Rokko Island Hospital-Clinical Research Committee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age 18 - 70 years, chronic kidney disease stage 3, 4 and 5, as defined by the Japanese Society of Nephrology (JSN), standard renoprotective treatment recommended by the JSN committee, their physical status and laboratory results maintained with variation of less than 30% during at least three consecutive measurements, for a minimum of 3 months after the first consultation, without evidence of urinary-tract infection or overt heart failure (New York Heart Association [NYHA] class III-IV) and acute cardiovascular acidents; and no history of allergic reaction to drugs, especially beta-adrenergic antagonists.
Exclusion criteria
Exclusion criteria: Exclusion criteria were: immediate need for renal replacement therapy; treatment-resistant oedema; need for treatment with corticosteroids, non-steroidal anti-inflammatory drugs, or immunosuppressive drugs; proteinuria greater than 10 g per day and hypoalbuminaemia less than 28 g/L (normal range 36&#8211;50 g/L); renovascular hypertension; malignant hypertension, myocardial infarction, or cerebrovascular accident in the year preceding the trial; severe peripheral vascular disease; severe congestive heart failure (NYHA III&#8211;IV); chronic hepatic disease (rise of serum aminotransferase concentration); connective-tissue disease; obstructive uropathy; cancer; chronic pulmonary disease; drug or alcohol misuse; pregnancy; and breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A combined renal outcome of a doubling of serum creatinine concentration and/or end-stage renal disease | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) estimated glomerular filtration rate 2) dairy proteinuria excretion 3) blood pressure, heart rate 4) cardiovascular events 5) cardiac ultrasound 6) blood neurohormones, hANP, and BNP levels | — |
Countries
Japan
Contacts
Public ContactNaoyuki Nakao
Rokko Island Hospital Division of Nephrology
Outcome results
None listed